These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14686996)

  • 21. Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds.
    Kontoyiannis DP
    Virulence; 2011; 2(3):257-8. PubMed ID: 21543881
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
    Radford SA; Johnson EM; Warnock DW
    Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Garcia-Effron G; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5136-8. PubMed ID: 16304186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
    Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
    Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal activity of amphotericin B and itraconazole against filamentous fungi: comparison of the Sensititre Yeast One and NCCLS M38--a reference methods.
    Carrillo-Muñoz AJ; Quindós G; Del Valle O; Hernández-Molina JM; Santos P
    J Chemother; 2004 Oct; 16(5):468-73. PubMed ID: 15565914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.
    Biancalana FS; Lyra L; Schreiber AZ
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4485-7. PubMed ID: 21690288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL; Moore CB; Denning DW
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
    J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
    Shah KB; Wu TG; Wilhelmus KR; Jones DB
    Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
    Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
    Cuenca-Estrella M; Ruiz-Díez B; Martínez-Suárez JV; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 1999 Jan; 43(1):149-51. PubMed ID: 10381115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.
    Sun QN; Fothergill AW; McCarthy DI; Rinaldi MG; Graybill JR
    Antimicrob Agents Chemother; 2002 May; 46(5):1581-2. PubMed ID: 11959605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
    González GM; Fothergill AW; Sutton DA; Rinaldi MG; Loebenberg D
    Med Mycol; 2005 May; 43(3):281-4. PubMed ID: 16010855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.
    Córdoba S; Rodero L; Vivot W; Abrantes R; Davel G; Vitale RG
    Int J Antimicrob Agents; 2008 Feb; 31(2):171-4. PubMed ID: 18054469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.